Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 20, Issue 4, 2002, Pages 900-910

  Yuan, Ang ^a   Yu, Chong Jen ^a   Luh, Kwen Tay ^a   Kuo, Sow Hsong ^a   Lee, Yung Chie ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; MESSENGER RNA; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; LUNG NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037083324     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.4.900     Document Type: Article

References (76)

1. What is the evidence that tumours are angiogenesis dependent?
2. Induction of angiogenesis during the transition from hyperplasia to neoplasia
3. The prognostic significance of tumor vascularity in intermediate-thickness (0.766-4.0 mm thick) skin melanoma: A quantitative histologic study
4. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma
5. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
6. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors
7. Tumor angiogenesis and rectal carcinoma
8. Relation of neovascularization to metastasis of non-small-cell lung cancer
9. Tumor angiogenesis correlates with histologic type and metastasis in non-small cell lung cancer
10. Angiogenesis in cancer, vascular, rheumatoid and other disease
11. Vascular endothelial growth factor in a potential tumor angiogenesis factor in human gliomas in vivo
12. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanism
13. Expression of vascular endothelial growth factor and its receptor: KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
14. Association of vascular endothelial growth factor expression with tumor angiogenesis and early relapse in primary breast cancer
15. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinoma
16. Prognostic value of vascular endothelia growth factor expression in gastric carcinoma
17. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
18. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
19. Prognostic value of vascular endothelial growth factor and its receptor Flt-I in squamous cell lung cancer
20. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
21. Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis
22. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis and angiogenesis
23. Inhibition of IL-8 attenuates angiogenesis in bronchogenic carcinoma
24. p53 mutation in human cancers
25. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
26. p53 function and dysfunction
27. Accumulation of p53 correlates with a poor prognosis in human lung cancers
28. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
29. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
30. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
31. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis
32. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer
33. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung cancer
34. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: Its association with turnout progression and p53 gene status
35. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53
36. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene
37. Histological typing of lung tumors
38. A new international staging system for lung cancer
39. Real-time quantitative RT-PCR after laser-assisted cell picking
40. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications
41. Molecular and biological properties of the vascular endothelial-growth-factor family of proteins
42. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils
43. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA
44. Alternatives to analysis of variance and the t test based on ranks
45. Nonparametric estimation from incomplete observations
46. Role of angiogenic factors: Coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma
47. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
48. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer
49. Wild type p53 can down-modulate the activity of various promotors
50. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53
51. Antioncogene p53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506)
52. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator Leflunomide
53. Clonal expression and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations
54. P53, guardian of the genome
55. Activating mutation in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form
56. The clinical significance of p53 aberrations in human tumors
57. Gain-of-function mutations in the tumor suppressor gene p53
58. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage
59. Postranslational regulation of p53 tumor suppressor protein function
60. Sensitivity of detection of heterozygous point mutations in p53 cDNAs by direct PCR sequencing
61. Oncogenic mutation of the p53 tumor suppressor: The demons of the guardian of the genome
62. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival
63. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins
64. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness
65. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotyes of human p53 mutation
66. Activation of C-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain
67. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report of LCSG 871
68. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development
69. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer
70. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
71. Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression
72. Lewis Y antigen expression and postoperative survival in non-small cell lung cancer
73. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma
74. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer
75. Expression of p53 oncoprotein in non-small cell lung cancer: A favorable prognostic factor
76. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells